Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 25, 2018 -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S. financial markets on Wednesday, May 2, 2018. Immune Design management will host a webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2018 to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 1088768.
About Immune Design
Immune Design is a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic immune cells to fight cancer and other chronic diseases. CMB305 and G100, the leading product candidates with broad potential in oncology, are based on the company’s two technology platforms that are potent stimulators of the immune system: ZVex® and GLAAS®. Both ZVex and GLAAS also have potential applications in infectious disease and allergy indications, which are being developed through ongoing pharmaceutical collaborations. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
Media Contact
Julie Rathbun
[email protected]
206-769-9219
Investor Contact
Sylvia Wheeler
[email protected]
